Algert Global LLC Grows Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Algert Global LLC increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 89.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 104,337 shares of the biopharmaceutical company's stock after purchasing an additional 49,354 shares during the quarter. Algert Global LLC owned 0.16% of Celldex Therapeutics worth $2,637,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CLDX. Price T Rowe Associates Inc. MD boosted its stake in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after purchasing an additional 676,771 shares during the period. American Century Companies Inc. boosted its position in Celldex Therapeutics by 46.5% in the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after buying an additional 193,093 shares during the period. Eversept Partners LP grew its stake in Celldex Therapeutics by 27.4% in the 4th quarter. Eversept Partners LP now owns 719,836 shares of the biopharmaceutical company's stock worth $18,190,000 after acquiring an additional 154,934 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter worth approximately $3,452,000. Finally, Silverarc Capital Management LLC increased its position in shares of Celldex Therapeutics by 82.5% during the fourth quarter. Silverarc Capital Management LLC now owns 264,560 shares of the biopharmaceutical company's stock worth $6,685,000 after acquiring an additional 119,560 shares during the period.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday. Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 target price on the stock. Finally, Morgan Stanley reduced their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $53.90.

Celldex Therapeutics Trading Down 6.1 %

Shares of CLDX stock traded down $1.19 during trading hours on Friday, reaching $18.33. 1,001,538 shares of the company's stock were exchanged, compared to its average volume of 889,846. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock's 50 day moving average is $18.99 and its 200-day moving average is $22.84. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -7.13 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.